¸ð½Ã´Â±Û ÇÁ·Î±×·¥ ÃÊ·ÏÁ¢¼ö »çÀüµî·Ï ¹ßÇ¥ÀÚ ¾È³» ¼ö»óÀÚ ¾È³» Çà»çÀå¾È³» ¼÷¹Ú¾È³» Ȩ
¸ðüžÆÀÇÇР  /    »ý½Ä³»ºÐºñÇР  /    ºÎÀÎÁ¾¾çÇР  /    ÀϹݺÎÀΰúÇÐ
Æ÷½ºÅÍ : ºÎÀÎÁ¾¾çÇÐ - ÀϽà : 2014³â 9¿ù 26ÀÏ(±Ý) ~ 2014³â 9¿ù 27ÀÏ(Åä)
- Àå¼Ò : EXHIBITION HALL B[1F]
(07:00~07:00) ÁÂÀå :
86-GO107:00~07:00 °­¿ì´ë
Àü³²´ëÇб³º´¿ø »êºÎÀΰú
Diagnostic accuracy of human papillomavirus genotyping
87-GO207:00~07:00 °­Á¤¹è
ÇѸ²ÀÇ´ë µ¿Åº¼º½Éº´¿ø »êºÎÀΰú
Malignant Perivascular Epithelioid Cell Tumor(PEComa) of the Uterus with Lung Metastasis
88-GO307:00~07:00 ±âÀº¿µ
°¡Å縯ÀÇ´ë ¼­¿ï¼º¸ðº´¿ø »êºÎÀΰú
A clinicopathological review of pulmonary metastasis from uterine cervical cancer.
89-GO407:00~07:00 ±è¿ÏÁÖ
°æ»ó´ëÇб³º´¿ø »êºÎÀΰú
An unusual presentation of a rectal duplication cyst accompanying large uterine myoma(case report)
90-GO507:00~07:00 ±è¿ë¼®
¼º±Õ°üÀÇ´ë °­ºÏ»ï¼ºº´¿ø »êºÎÀΰú
Effects of hemostatic sealant in preservation of ovarian reserve during laparoscopic ovarian cystectomy
91-GO607:00~07:00 ±èÅÂÈÆ
¿øÀÚ·ÂÀÇÇпø »êºÎÀΰú
Pretreatment Neutrophil:Lymphocyte Ratio and Platelet:Lymphocyte Ratio as a Prognostic factor in locally advanced cervical cancer
92-GO707:00~07:00 ±èÈñ½Â
¼­¿ï´ëÇб³º´¿ø »êºÎÀΰú
Conventional Versus Nerve-sparing Radical Surgery for Cervical Cancer: A Meta-analysis Including 2,280 Women With Cervical Cancer From 21 Comparative Studies
93-GO807:00~07:00 ±èÈñ½Â
¼­¿ï´ëÇб³º´¿ø »êºÎÀΰú
Success factors of laparoscopic nerve-sparing radical hysterectomy for preserving bladder function in patients with cervical cancer: a protocol-based prospective cohort study
94-GO907:00~07:00 ·ùÁöÀ±
¼º±Õ°üÀÇ´ë »ï¼º¼­¿ïº´¿ø »êºÎÀΰú
The role of SK1 (sphingosine kinase 1) in epithelial ovarian cancer
95-GO1007:00~07:00 ·ùÇö°æ
Àü³²´ëÇб³º´¿ø »êºÎÀΰú
The prognostic value of squamous cell carcinoma antigen in the prediction of tumor recurrence in cervical carcinoma patients with various clinical characteristics.
96-GO1107:00~07:00 ¹Ú¿¹±Ô
´Ü±¹´ëÇб³º´¿ø »êºÎÀΰú
Case report: Deep vulva malignant melanoma in premenopausal woman
97-GO1207:00~07:00 ¹Ú¿¹±Ô
´Ü±¹´ëÇб³º´¿ø »êºÎÀΰú
Case report: Pure-type Large cell Neuroendocrine carcinoma of the ovary in premenopausal woman
98-GO1307:00~07:00 ¹ÚÁ¤¹Î
¼º±Õ°üÀÇ´ë »ï¼º¼­¿ïº´¿ø »êºÎÀΰú
The Effects of Body Mass Index on Survival Outcomes in Patients With Cervical Carcinoma (IB1 to IVA)
99-GO1407:00~07:00 ¹ÚÁؽÄ
¼øõÇâÀÇ´ë ºÎõº´¿ø »êºÎÀΰú
Paratubal Serous Bordeline Tumor: a Case Report
100-GO1507:00~07:00 ¹ÚÁؽÄ
¼øõÇâÀÇ´ë ºÎõº´¿ø »êºÎÀΰú
Benign Cystic Mesothelioma which Can Mimic Gynecologic Malignancies: a Case Report
101-GO1607:00~07:00 ¹Úö¹Î
Á¦ÁÖ´ëÇб³º´¿ø »êºÎÀΰú
Primary omental torsion diagnosed during hysterectomy
102-GO1707:00~07:00 ¹ÚÈ¿°æ
¾ÆÁÖ´ëÇб³º´¿ø »êºÎÀΰú
Patterns of recurrence and survival after abdominal versus laparoscopic/robotic radical hysterectomy in patients with early cervical cancer
103-GO1807:00~07:00 ¹èÈ¿¼÷
°í·ÁÀÇ´ë ¾È¾Ïº´¿ø »êºÎÀΰú
Atypical endometriosis: Morphologic, immunohistochemical and molecular changes
104-GO1907:00~07:00 ¹èÈ¿¼÷
°í·ÁÀÇ´ë ¾È¾Ïº´¿ø »êºÎÀΰú
Sexual function and Treatment Modalities in Cervical Cancer Patients: Systematic Review and Meta-analysis
105-GO2007:00~07:00 ¹éÀ̼±
¼º±Õ°üÀÇ´ë »ï¼º¼­¿ïº´¿ø »êºÎÀΰú
Survival analysis of Revised 2013 FIGO Staging Classification of Epithelial Ovarian Cancer and Comparison with Previous FIGO Staging Classification
106-GO2107:00~07:00 º¯½Â¿ø
°¡Å縯ÀÇ´ë ÀÇÁ¤ºÎ¼º¸ðº´¿ø »êºÎÀΰú
Efficacy of preemptive port site local analgesia for wound pain after gynecologic laparoendoscopic single-site surgery
107-GO2207:00~07:00 º¯½Â¿ø
°¡Å縯ÀÇ´ë ÀÇÁ¤ºÎ¼º¸ðº´¿ø »êºÎÀΰú
Vaginal cuff closure with unidirectional barbed suture during total laparoscopic hysterectomy is a safe and feasible procedure.
108-GO2307:00~07:00 º¯Á¤¹Ì
ÀÎÁ¦ÀÇ´ë ºÎ»ê¹éº´¿ø »êºÎÀΰú
The importance of diagnosis of endometrial cancer arising from atypical complex hyperplasia
109-GO2407:00~07:00 ¼­µ¿ÈÆ
¼­¿ï´ëÇб³ ºÐ´çº´¿ø »êºÎÀΰú
Critical points for inexperienced surgeons to successfully perform laparoscopic radical hysterectomy versus abdominal radical hysterectomy in early-stage cervical cancer: matched-case comparisons
110-GO2507:00~07:00 ¼­Á¤¿ø
¼­¿ï´ëÇб³º´¿ø »êºÎÀΰú
Dose diabetes medication reduce recurrence of endometrial cancer ?
111-GO2607:00~07:00 ¼®ÇýÁø
¿ï»êÀÇ´ë ¼­¿ï¾Æ»êº´¿ø »êºÎÀΰú
Robot-assisted radical hysterectomy combined with vaginal approach for the patients with bulky cervical cancer : feasibility and operative results
112-GO2707:00~07:00 ¼ÕÁÖÇõ
¾ÆÁÖ´ëÇб³º´¿ø »êºÎÀΰú
Prediction of lymph node metastasis in patients with apparent early endometrial cancer
113-GO2807:00~07:00 ¼Û¹ÎÁ¾
°¡Å縯ÀÇ´ë ´ëÀü¼º¸ðº´¿ø »êºÎÀΰú
Single port laparoscopic transumbilical extraperitoneal paraaortic lympadenectomy for surgical staging in locally advanced cervical cancer
114-GO2907:00~07:00 ¼Û¹ÎÁ¾
°¡Å縯ÀÇ´ë ´ëÀü¼º¸ðº´¿ø »êºÎÀΰú
Anti-cancer effect of bee venom via increase of death receptor expression and inactivation of NF-B in human cervical cancer
115-GO3007:00~07:00 ¼ÛÀº¼·
ÀÎÇÏ´ëÇб³º´¿ø »êºÎÀΰú
he Clinical Impact Of Human Papilloma Virus On the Patients With ASCUS/LSIL
116-GO3107:00~07:00 À±°¡¿µ
ºÎ»ê´ëÇб³º´¿ø »êºÎÀΰú
Simultaneous Borderline mucinous tumor, Mature cystic teratoma and Endometriosis in the Same Ovary
117-GO3207:00~07:00 À±¾Ö¶ó
¼º±Õ°üÀÇ´ë »ï¼º¼­¿ïº´¿ø »êºÎÀΰú
Therapeutic Targeting of C-MET in Ovarian Clear-Cell Carcinoma
118-GO3307:00~07:00 ÀÌ´ë¿ì
°¡Å縯ÀÇ´ë ºÎõ¼º¸ðº´¿ø »êºÎÀΰú
Premature hepatic metastasis of ovarian yolk sac tumor
119-GO3407:00~07:00 À̹ξÆ
ÀÌÈ­¿©ÀÚ´ëÇб³ ÀÇ°ú´ëÇÐºÎ¼Ó ¸ñµ¿º´¿ø »êºÎÀΰú
Micronutrients and Clearance of Human Papillomavirus: a Meta-Analysis
120-GO3507:00~07:00 À̹æÇö
¼­¿ï´ëÇб³ ºÐ´çº´¿ø »êºÎÀΰú
Onset of chemotherapy-induced severe neutropenia in patient with ovarian cancer
121-GO3607:00~07:00 À̹æÇö
¼­¿ï´ëÇб³ ºÐ´çº´¿ø »êºÎÀΰú
The effect of human papillomavirus genotyping on triage of atypical squamous cells of undetermined significance
122-GO3707:00~07:00 ÀÌ»óÈÆ
¿ï»ê´ëÇб³º´¿ø »êºÎÀΰú
Ovarian Microcystic Stromal Tumor (MCST): a Novel Extracolonic Tumor in Familial Adenomatous Polyposis
123-GO3807:00~07:00 À̽¹Ì
¼­¿ï´ëÇб³º´¿ø »êºÎÀΰú
Long-term follow-up study of adult-type ovarian granulosa cell tumor
124-GO3907:00~07:00 À̽ÅÈ­
¿ï»êÀÇ´ë ¼­¿ï¾Æ»êº´¿ø »êºÎÀΰú
Prognostic significance of treatment-induced pathologic remission and adjuvant chemotherapy after interval cytoreduction following neoadjuvant chemotherapy in epithelial ovarian cancer
125-GO4007:00~07:00 ÀÌ¿¬¾Æ
Ãæ³²´ëÇб³º´¿ø »êºÎÀΰú
a case of Liposarcoma like subserosal myoma with endometrial carcinoma in uterus
126-GO4107:00~07:00 ÀÌ¿µÀç
Â÷ÀÇ°úÇдëÇб³ ºÐ´çÂ÷º´¿ø »êºÎÀΰú
³­¼Ò ±âÇüÁ¾ÀÇ ¾Ç¼ºµµ ¹× Á¾¾ç Å©±â¿Í ¼ö¼ú Àü CA19-9ÀÇ »ó°ü°ü°è
127-GO4207:00~07:00 ÀÌ¿ÏÈ£
Àü³²´ëÇб³º´¿ø »êºÎÀΰú
Is vaginal cytology and CA-125 measurement useful to detect recurrent endometrial cancer in postoperative patients ?
128-GO4307:00~07:00 ÀÌ¿ø¹«
ÇѾç´ëÇб³º´¿ø »êºÎÀΰú
The prognostic significance of steroid sulfatase in patients with endometrial cancer
129-GO4407:00~07:00 ÀÌÀ¯°æ
Phosphorylation of AKT and hTERT expression are associated with prognosis of epithelial ovarian carcinomas
130-GO4507:00~07:00 ÀÌÀ±Èñ
Ä¥°î°æºÏ´ëÇб³º´¿ø »êºÎÀΰú
The prognosis of hydronephrosis after treatment in gynecologic malignancy.
131-GO4607:00~07:00 ÀÌÀοÁ
¿¬¼¼´ëÇб³ ¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú
Clinicopathologic characteristics of ovarian Sertoli-Leydig cell tumors.
132-GO4707:00~07:00 ÀÌÁöÇý
°í·ÁÀÇ´ë ±¸·Îº´¿ø »êºÎÀΰú
T-cell immune response to human papillomavirus 16 for predicting the cytological progress
133-GO4807:00~07:00 ÀÌÇý³²
Â÷ÀÇ°úÇдëÇб³ °­³²Â÷º´¿ø »êºÎÀΰú
ÀÚ±ÃÆòÈ°±ÙÀ°Á¾ ¹× Àڱ󻸷±âÁúÀ°Á¾ÀÇ ´ÜÀϱⰣ¿¡¼­ÀÇ 14³â°£ÀÇ °æÇè
134-GO4907:00~07:00 ÀåÇϱÕ
°¡Å縯ÀÇ´ë ¼­¿ï¼º¸ðº´¿ø »êºÎÀΰú
Retrospective analysis of 63 cases with endometrial stromal sarcoma, leiomyosarcoma and carcinosarcoma in CMC, Korea, 1990-2013.
135-GO5007:00~07:00 ÀüÇý°æ
¼º±Õ°üÀÇ´ë »ï¼º¼­¿ïº´¿ø »êºÎÀΰú
High-throughput molecule screen in clear cell carcinoma
136-GO5107:00~07:00 Á¤¾ð¼®
ÇѾç´ëÇб³º´¿ø »êºÎÀΰú
Laparoscopic para-aortic lymphadenectomy up to the renal vein level : Surgical approach and outcomes from single surgical team 10-year experience
137-GO5207:00~07:00 Á¤¿¬¼ö
±¹¹Î°Ç°­º¸Çè°ø´Ü Àϻ꺴¿ø »êºÎÀΰú
ANTIPROLIFERATIVE AND APOPTOTIC ACTIVITY OF MÜLLERIAN INHIBITING SUBSTANCE (MIS) AND CALCITRIOL CO-TREATMENT OF OVARIAN CANCER CELL LINES
138-GO5307:00~07:00 Á¤¿µ½Å
¿¬¼¼´ëÇб³ ¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú
Total vaginal necrosis after radiation for recurrent cervical cancer : a case report
139-GO5407:00~07:00 Á¤À±Áö
°¡Å縯ÀÇ´ë ¼­¿ï¼º¸ðº´¿ø »êºÎÀΰú
Müllerian inhibiting substance functions as tumor suppressor by regulating multiple components of cancer-related pathways in human uterine endometrial cancer
140-GO5507:00~07:00 Á¤Çý¿ø
°è¸íÀÇ´ë µ¿»êÀÇ·á¿ø »êºÎÀΰú
The Treatment of Pazopanib on Vulvar Epithelioid Sarcoma: A Case Report and Review of Literature
141-GO5607:00~07:00 Á¶¿µÀç
¼º±Õ°üÀÇ´ë »ï¼º¼­¿ïº´¿ø »êºÎÀΰú
Anti-cancer effect of Linalool in Epithelial Ovarian Cancer
142-GO5707:00~07:00 Á¶¿µÀç
¼º±Õ°üÀÇ´ë »ï¼º¼­¿ïº´¿ø »êºÎÀΰú
Patient-derived xenograft models identify HER2 as a therapeutic target in HER2-amplified cervical cancer
143-GO5807:00~07:00 Á¶Àººñ
ÀÎÁ¦ÀÇ´ë ºÎ»ê¹éº´¿ø »êºÎÀΰú
Metastatic choriocarcinoma as initial presentation of small bowel perforation in absence of primary uterine lesion: A case report
144-GO5907:00~07:00 Á¶Çý¿¬
ÇѸ²ÀÇ´ë µ¿Åº¼º½Éº´¿ø »êºÎÀΰú
Comparison of HE4, CA125, and risk of ovarian malignancy algorithm (ROMA) for the differential diagnosis of ovarian cancer from benign pelvic mass
145-GO6007:00~07:00 Â÷ÁÖÀº
ÀÎÁ¦ÀÇ´ë ºÎ»ê¹éº´¿ø »êºÎÀΰú
Carcinoid tumor arising in ovarian mature cystic teratoma and coexisting mature cystic teratoma of omentum, peritoneum and ovary : A Case Report
146-GO6107:00~07:00 ÃÖ¿¹Áø
ÀÎÁ¦ÀÇ´ë ÀÏ»ê¹éº´¿ø »êºÎÀΰú
Choriocarcinomatosis dedifferentiation from adenocarcinoma of the uterine cervix: A case report
147-GO6207:00~07:00 ÃÖÀ±Áø
°¡Å縯ÀÇ´ë ¼­¿ï¼º¸ðº´¿ø »êºÎÀΰú
Parents¡¯ knowledge and attitude towards HPV vaccination in Korea :Implications for Health communications
148-GO6307:00~07:00 ÃÖÀοµ
°æ»ó´ëÇб³º´¿ø »êºÎÀΰú
Adenoid cystic carcinoma of Bartholin¡¯s gland in menopause women
149-GO6407:00~07:00 ÃÖÇýÁø
°í·ÁÀÇ´ë ±¸·Îº´¿ø »êºÎÀΰú
Clinical utility of dual-phase 18F-FDG PET/CT for predicting the outcome in patients with cervical carcinoma
150-GO6507:00~07:00 Çѽ¼ö
Áß¾Ó´ëÇб³º´¿ø »êºÎÀΰú
The value of preoperative platelet count in the prediction of prognosis in patients with endometrial cancer
151-GO6607:00~07:00 ÇÑ¿ì¼®
¿ï»êÀÇ´ë ¼­¿ï¾Æ»êº´¿ø »êºÎÀΰú
Prognostic significance of serum CA-125 levels rising within the normal range in patients with epithelial ovarian cancers, and a complete clinical response
152-GO6707:00~07:00 Thi My Hien Nguyen
Áß¾Ó´ëÇб³º´¿ø »êºÎÀΰú
ITM2A, down-regulated in serous ovarian cancer patients has anti-tumoral activity of ovarian cancer cells by inducing G2/M cell cycle arrest.
ÀϹݿ¬Á¦ : ºÎÀÎÁ¾¾çÇÐ - ÀϽà : 2014³â 9¿ù 26ÀÏ (±Ý)
- Àå¼Ò : ¿¡¸Þ¶öµåȦ B[3F]
GO1-GO4 (08:20~09:00) ÁÂÀå : ·ù±â¼º(°¡Å縯ÀÇ´ë)
GO108:20~08:30 ³²ÀºÁö
¿¬¼¼´ëÇб³ ¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú
Pancreatic adenocarcinoma up-regulated factor (PAUF) expression in ovarian mucinous adenocarcinoma associated with a poor prognosis
GO208:30~08:40 ¾ç¼±¿µ
°í·ÁÀÇ´ë ±¸·Îº´¿ø »êºÎÀΰú
ASC-US and LSIL triage in Korean women: Revisiting the 2012 ASCCP screening guidelines
GO308:40~08:50 ±èÁ¤Àº
°Ç±¹´ëÇб³º´¿ø »êºÎÀΰú
Prediction model for 30-day morbidity after gynecological malignancy surgery
GO408:50~09:00 ÇãÀºÁø
¼º±Õ°üÀÇ´ë »ï¼º¼­¿ïº´¿ø »êºÎÀΰú
The impact of the interval from surgery to initiation of chemotherapy (ISC) on survival in advanced epithelial ovarian cancer
GO5-GO8 (09:00~09:40) ÁÂÀå : ±èÀçÈÆ(¿¬¼¼ÀÇ´ë)
GO509:00~09:10 ¹èÈ¿¼÷
±¹¸³¾Ï¼¾ÅÍ
Predictive factor and risk group analysis for the local recurrence/persistent disease in cervical cancer patients who underwent primary concurrent chemoradiotherapy (CCRT)
GO609:10~09:20 ¹éÀ̼±
¼º±Õ°üÀÇ´ë »ï¼º¼­¿ïº´¿ø »êºÎÀΰú
Laparoscopic surgical management of localized recurrent ovarin cancer
GO709:20~09:30 ÀÓ¸íö
±¹¸³¾Ï¼¾ÅÍ
A simple new technique of diaphragmatic peritonectomy: hand-pushing down with anchoring both ends
GO809:30~09:40 ÀÌÁ¤¿ø
¼º±Õ°üÀÇ´ë »ï¼º¼­¿ïº´¿ø »êºÎÀΰú
Anti-angiogenic Effect of Itraconazole in Epithelial Ovarian Cancer
GO9-GO12 (09:40~10:20) ÁÂÀå : ³²°èÇö(¼øõÇâÀÇ´ë)
GO909:40~09:50 ¼­µ¿ÈÆ
¼­¿ï´ëÇб³ ºÐ´çº´¿ø »êºÎÀΰú
Survival impact of surgical spillage in stage I clear cell carcinoma of ovary: Korean multicenter study.
GO1009:50~10:00 Á¤ÇʽÂ
¿ï»êÀÇ´ë ¼­¿ï¾Æ»êº´¿ø »êºÎÀΰú
Poor prognosis after conservative surgery in stage I mucinous epithelial ovarian cancer
GO1110:00~10:10 ÀÌÁ¤À±
¼­¿ï´ëÇб³º´¿ø »êºÎÀΰú
A low-risk group for parametrial involvement is accurately identified by criteria used in ongoing studies and new criteria using MRI in microscopic stage IB1 cervical cancer
GO1210:10~10:20 ÀÓ¸íö
±¹¸³¾Ï¼¾ÅÍ
Colon cancer as a second primary cancer after endometrial cancer based on shared etiology: a proof of concept study
GO13-GO16 (11:00~11:40) ÁÂÀå : ¹®Çý¼º(ÀÌÈ­ÀÇ´ë)
GO1311:00~11:10 ±â°æµµ
°­µ¿°æÈñ´ëÇб³º´¿ø »êºÎÀΰú
XAF1 is activated by TNF¥á and mediated TNF¥á-induced apoptosis in ovarian cancer cells
GO1411:10~11:20 ÀÓ°¡¿ø
¿¬¼¼´ëÇб³ ¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú
Long non-coding RNA HOXA11as is associated with survival in advanced epithelial ovarian cancer
GO1511:20~11:30 ±¸À¯Áø
°í·ÁÀÇ´ë ±¸·Îº´¿ø »êºÎÀΰú
Discordance of histopathologic diagnosis between colposcopy-guided biopsy and conization in high-grade cervical intraepithelial lesions
GO1611:30~11:40 Á¤ÇʽÂ
¿ï»êÀÇ´ë ¼­¿ï¾Æ»êº´¿ø »êºÎÀΰú
Diagnostic value of combined 18F-FDG positron emission tomography/computed tomography in recurrent epithelial ovarian cancer with non-disseminated lesions
GO17-GO20 (11:40~12:20) ÁÂÀå : À̼±°æ(°æÈñÀÇ´ë)
GO1711:40~11:50 ÀÌÁöÀ±
¿¬¼¼ÀÇ´ë °­³²¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú
Makorin Ring Finger Protein 1 (MKRN1) as an adjunct marker in liquid-based cervical cytology
GO1811:50~12:00 ÀÌÁö¼±
¾ÆÁÖ´ëÇб³º´¿ø »êºÎÀΰú
Predicting model for lymph node metastasis using preoperative tumor grade, transvaginal ultrasound, and serum CA-125 level in patients with endometrial cancer
GO1912:00~12:10 ·ù±âÁø
°í·ÁÀÇ´ë ¾È¾Ïº´¿ø »êºÎÀΰú
Clinical Significance of HPV DNA Co-testing in Korean Women with atypical squamous cells-cannot exclude high-grade squamous intraepithelial lesion (ASC-H).
GO2012:10~12:20 ÀÌÁö¿µ
Ä¥°î°æºÏ´ëÇб³º´¿ø »êºÎÀΰú
Cytokeratin 19 and human papilloma virus in lymph node of cervical cancer patients with intermediate risk factors
GO21-GO24 (12:20~13:00) ÁÂÀå : À̱âÇå(°üµ¿ÀÇ´ë)
GO2112:20~12:30 ½Å¼ÒÁø
°è¸íÀÇ´ë µ¿»êÀÇ·á¿ø »êºÎÀΰú
The Hsp90 Inhibitor SY-016, Induces G2/M Arrest and Apoptosis in Paclitaxel-resistant Human Ovarian Cancer Cells
GO2212:30~12:40 À̹ξÆ
ÀÌÈ­¿©ÀÚ´ëÇб³ ÀÇ°ú´ëÇÐºÎ¼Ó ¸ñµ¿º´¿ø »êºÎÀΰú
Synergistic effect of HPV E6/E7 siRNA in combination with Cisplatin on Basal dynamic studies of TP53
GO2312:40~12:50 ¼Õ±Ý¼±
¿¬¼¼ÀÇ´ë °­³²¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú
Chemosensitivity testing based on gene expression profiling in patients with ovarian cancer
GO2412:50~13:00 ±èÇüÁÖ
¿¬¼¼ÀÇ´ë °­³²¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú
Forkhead box P1 (Foxp1) in cervical cancer
GO25-GO28 (14:00~14:40) ÁÂÀå : °í¼®ºÀ(´ë±¸°¡Å縯ÀÇ´ë)
GO2514:00~14:10 ±èÁ¤Áø
¼º±Õ°üÀÇ´ë °­ºÏ»ï¼ºº´¿ø »êºÎÀΰú
Comparison of barbed suture versus traditional suture in laparoendoscopic single-site myomectomy
GO2614:10~14:20 ¼ÕÁÖÇõ
¾ÆÁÖ´ëÇб³º´¿ø »êºÎÀΰú
Cutoff value of pre- and post-cone HR-HPV load predicting residual/recurrent disease after conization in high-grade intraepithelial neoplasia and microinvasive carcinoma of the uterine cervix
GO2714:20~14:30 À̽ÂÁ¤
°æºÏ´ëÇб³º´¿ø »êºÎÀΰú
Single-port nerve sparing laparoscopic radical hysterectomy with extended node dissection for cervical cancer
GO2814:30~14:40 ¹èÀ縸
ÇѾç´ëÇб³º´¿ø »êºÎÀΰú
Laparoscopic Cytoreductive Surgery in Women with Epithelial Ovarian Cancer
GO29-GO33 (14:40~15:30) ÁÂÀå : ÇѼ¼ÁØ(Á¶¼±ÀÇ´ë)
GO2914:40~14:50 ±èÁöÈñ
¼­¿ï´ëÇб³º´¿ø »êºÎÀΰú
Detecting asymptomatic recurrence in early stage endometrial cancer- the value of vaginal cytology, imaging studies and CA-125
GO3014:50~15:00 ±è¿¬¼±
°í·ÁÀÇ´ë ±¸·Îº´¿ø »êºÎÀΰú
Clinical impact of the number of the retrieved pelvic lymph nodes in epithelial ovarian cancer
GO3115:00~15:10 ±èÈñÁ¤
¿¬¼¼´ëÇб³ ¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú
Steroid Receptor Activator induces tumor proliferation and invasion through the Notch pathway in the human ovarian cancer
GO3215:10~15:20 ¼­µ¿¼ö
ºÎ»ê´ëÇб³º´¿ø »êºÎÀΰú
DDX4 (DEAD box polypeptide 4) colocalizes with cancer stem cell marker CD133 in ovarian cancers
GO3315:20~15:30 ÀÌ´Ù¿ë
¼­¿ï´ëÇб³º´¿ø »êºÎÀΰú
Prognosis and Associated Factors in Neuroendocrine Cervical Carcinoma (NECC)